Design Therapeutics Reports Q3 GAAP EPS of -$0.32, Exceeding Estimates
Design Therapeutics (DSGN) reported third-quarter GAAP earnings per share of -$0.32, slightly beating analyst expectations by $0.02. The company maintains a solid liquidity position, reporting $208.6 million in cash, cash equivalents, and investment securities as of September 30, 2026. Looking ahead, the biotechnology firm is focusing on its Friedreich ataxia program. Management plans to initiate registrational feasibility studies for DT-216P2 in Q4 2026, with 12-week clinical results expected in Q1 2027. Following these updates, Wells Fargo has upgraded the company to an 'overweight' rating.
Topics: analyst upgrade cash position clinical trial updates earnings beat